When Israeli 3D printing company Nano Dimension gets coverage in the news, the discussion generally revolves around the intensive and long-awaited development of their electronic 3D printing system, the DragonFly2020. Since unveiling their desktop electronic 3D printer towards the end of last year, the company has had a momentous start to 2016. Aside from preparing for the manufacturing and distribution of the DragonFly2020, Nano Dimension has been working to develop a 3D printable nickel nano ink in collaboration with Tel Aviv University, and has also listed the company to begin trading on the NASDAQ.
With all of the developments taking place with their electronic 3D printing technology, it’s hard to imagine that the Nano Dimension team currently has any time to pursue other pivotal 3D printing projects. Well, it looks as if the electronics 3D printing company will indeed be venturing into other research areas, this time with 3D bioprinting. Collaborating with the premier stem cell culturing solutions provider Accellta Ltd., which is based in Haifa, Israel, Nano Dimension has just announced that they’ve successfully lab-tested a proof of concept 3D bioprinter for producing stem cell-derived tissues.
“Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies,” noted Accellta’s Chairman and CEO, Dr. Itzchak Angel. ” We hope and believe that this will bring the mutual capabilities and know-how of both companies to create 3D bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision 3D bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development. We are very excited about these initial results and what the future holds.”
The collaborative feasibility study, which was conducted over the second quarter of 2016, shows that their combined knowledge and technology has enabled the two companies to 3D print viable stem cells with a modified 3D printer. Utilizing Nano Dimension’s highly precise inkjet 3D printing capabilities, along with Accellta’s 15 years of experience in developing stem cell suspension technologies, their study thus far has proved to be a successful one. Working together, the two companies have showcased their potential to accelerate high fidelity and high viability production of living cellular products.
“3D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control and viability as well as cell availability and bio-ink technologies,” said Amit Dror, CEO of Nano Dimension. “By combining our high speed, high precision inkjet capabilities with Accellta’s stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable 3D printing at high resolution and high volumes.”
According to IDTechEx, the value of the 3D bioprinting market is projected to reach $6 billion by 2024, and is expected to improve a number of medically-driven areas, including pre-clinical drug discovery and testing, cosmetics safety testing, toxicology assays, and of course, tissue printing. By utilizing high precision 3D bioprinting and differentiation of stem cells into required tissues, Nano Dimension and Accellta are on the brink of enabling even greater capabilities for 3D bioprinting. The joint research may soon turn into a joint venture too, as both companies are considering the formation of an entirely new entity together in order to continue investigating future bioprinting solutions and raise funding for the continuation of their research.
Although Nano Dimension may seem fixated on electronics 3D printing technology at times, their true aim seems to be advancing their 3D inkjet technology in a multitude of ways. It’s clear that their recent developments in 3D printed electronics and circuit boards have helped set the stage for their collaborative multi-material bioprinting research, which could soon help thrust them forth into the high-demand medical market, much like they’re already set to do within the electronics industry in the near future. What do you think of this latest industry partnership? Discuss further in the Nano Dimension & Accellta Teaming up to Further 3D Printing forum over at 3DPB.com.
You May Also Like
Digilab: On the State of Bioprinting Today
In a recent interview with Digilab‘s CEO Sidney Braginsky, Senior Applications Manager Igor Zlatkin, and John Moore, President and COO, 3DPrint.com got a glimpse of the focus, future, and advances...
Wikifactory’s Docubot Challenge Creates a Hardware Solution for Documentation
International startup Wikifactory, established in Hong Kong last June, is a social platform for collaborative product development. Co-founded by four makers, and until recently counting 3DPrint.com Editor-in-Chief Joris Peels as a member...
Kickstarter Campaign Continues for High-Resolution Jewelry 3D Scanner
Ukrainian company D3D-s was founded four years ago by father and son team Leonid and Denys Nazarenko, and last year they successfully raised $250,000 through Kickstarter for their first desktop 3D...
Interview with Formalloy’s Melanie Lang on Directed Energy Deposition
When I met Melanie Lang at RAPID a lot of the buzz on the show floor was directed at her startup Formalloy. Formalloy has developed a metal deposition head that...
View our broad assortment of in house and third party products.